22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech
19 November 2026
Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative, global ones. In order to address the main challenge of R&D productivity, PPM professional serve as a link between operational teams and senior management level. They have the role to translate information, analyses, value, risks into clear message to serve the company strategy and help organisation to take major decisions on business. Management has to focus more on value, business decision from really early stage in order to predict potential of products or molecules and forecast new partnerships or extended collaboration.
The Marcus Evans 22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech conference will bring together portfolio and project leaders from pharmaceutical and biotech organisations to strengthen portfolio decision-making amid investment constraints, scientific uncertainty and shifting strategic priorities. Delegates will explore how to sharpen asset prioritisation, modernise governance and align resources with the programmes that offer the greatest strategic value. Sessions will examine how stronger data foundations, advanced analytics and AI can improve forecasting, scenario planning and portfolio insights, while maintaining appropriate human oversight. The conference will also address resource bottlenecks, cross-functional alignment and decision accountability, equipping leaders with practical approaches to translate portfolio strategy into execution and build more agile, resilient R&D portfolios.
Past speakers include:
• Erin Mulrooney, Director, Portfolio Management, Daiichi Sankyo
• Ananya Jain, Portfolio Management Lead, Biogen
• Neha Doshi, Associate Director, Portfolio Strategy & Analytics, Gilead Sciences
• Marisol Plaza, Sr. Director of IT, Project and Program Management, Bausch Health
• Daniel Patrick, former Executive Director, Portfolio Management, Regeneron Pharmaceuticals
• Ritesh Sanghvi, Vice President Due Diligence, Integration and Divestitures, Ipsen
Special discounts available to Pharmaceutical Tech members! For more information please contact: Stefanos Ioannou, Digital Media and PR Executive at stefanosi@marcusevanscy.com or visit: https://tinyurl.com/2s3nvwmk